practice areas
bar admissions
- California
- Pennsylvania
- San Francisco
-
One Market, Spear Street Tower
San Francisco, CA 94105-1596
Phone: 415.442.1368
Fax: 415.442.1001
Benjamin H. Pensak is an associate in Morgan Lewis's Business and Finance Practice. Mr. Pensak focuses his practice in the life sciences industry, advising public and private biotechnology, pharmaceutical, and medical device companies based in the U.S. and abroad on general corporate and transactional matters. Mr. Pensak advises his clients on a variety of mission-critical, usually technology-based, transactions including negotiation and structuring of acquisitions, divestitures, joint ventures, corporate partnering, licensing, and other complex collaborations. Related matters include drafting and negotiating technical contractual arrangements for drug discovery, development, manufacture and supply, marketing, and outsourcing among life sciences companies, universities, and other research organizations.
Mr. Pensak received his J.D. from the University of Michigan Law School in 2006, where he was an associate editor for the Michigan Journal of International Law. Mr. Pensak received his B.A., with honors, in religion from Wesleyan University, while conducting a range of microbiology research focused primarily on gene therapy.
Mr. Pensak is admitted to practice in California and Pennsylvania.
Selected Representations
- Auxilium Pharmaceuticals in its collaboration with Actelion for the development and commercialization of Xiaflex® in Canada, Mexico, Brazil, and Australia
- Lundbeck in its up to $1.8 billion co-development and co-commercialization global alliance with Otsuka Pharmaceutical for up to five innovative psychiatric and neuroscience products worldwide
- Eli Lilly in its transfer of U.S. rights to sepsis drug Xigris® to BioCritica, a newly created biotech company jointly owned by Lilly, Care Capital, and NovaQuest Capital
- Auxilium Pharmaceuticals in its up to $262 million development, commercialization, and supply collaboration with Asahi Kasei for Xiaflex® in Japan
- Onyx Pharmaceuticals in its more than $300 million development and commercialization collaboration with Ono Pharmaceutical for Carfilzomib and ONX-0912 in oncology indications in Japan
- Diamyd Medical AB in its up to $625 million license, development, and commercialization agreement with Ortho-McNeil-Janssen Pharmaceuticals focused on GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions
- Smiths Detection in its collaboration with Novartis Diagnostics relating to Smiths' Bio-Seeq platform and LATE-PCR technology for use in a range of point-of-care diagnostic tests
- Auxilium Pharmaceuticals in its up to $485 million development, commercialization, and supply collaboration with Pfizer for Xiaflex® in Europe and Eurasia
- Takeda in its $100 million up-front and up to $1 billion development and commercialization collaboration and technology transfer transaction with Alnylam relating to RNAi therapeutics
- Adolor in its up to $265 million development and commercialization collaboration with Pfizer for delta opioid agonists
- EUSA in its acquisition of one marketed product and license of two other products in development from Innocoll Pharmaceuticals
- Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
- Solstice in its up to €41 million development and commercialization collaboration with Eisai for the European rights to Neurobloc
education
- University of Michigan Law School, 2006, J.D.
- Wesleyan University, 2002, B.A., With Honors